Cellf BIO in the news Release by AAAS, American Association for the Advancement of Sciences, highlights some of the innovative regenerative engineering research Cellf BIO's Founder & CEO, Dr. Khalil N Bitar, Ph.D., AGAF, has been working on. "Researchers at Wake Forest Institute for Regenerative Medicine have reached important milestones in their quest to engineer replacement tissue in the lab to treat digestive system conditions - from infants born with too-short bowels to adults with inflammatory bowel disease, colon cancer, or fecal incontinence." See full article below https://lnkd.in/d_R8J_7
关于我们
Cellf BIO specializes in regenerative medicine treatments, including bioengineered tissue and cell therapies. A clinical-stage biotherapeutics company advancing regenerative cell therapy candidates for the treatment of neurodegenerative diseases, with a focus on the Gut & Brain Axis. Cellf BIO manufactures bioengineered sphincters using autologous smooth muscle and progenitor cells that restore the dysfunctional internal anal sphincter, the root cause of Fecal Incontinence. This new product, called a BioSphincter?, allows the patient to regain full control of bowel movements and rejuvenate their quality of life. Cellf BIO is developing cell therapies for other indications like Gastroparesis.
- 网站
-
https://www.cellfbio.com
Cellf BIO, Inc.的外部链接
- 所属行业
- 生物技术
- 规模
- 2-10 人
- 总部
- Richmond，Virginia
- 类型
- 私人持股
- 创立
- 2014
地点
Cellf BIO, Inc.员工
动态
-
Happy to share a great article highlighting CELLF-BIO's founder and CEO, Dr. Khalil Bitar, and Dr. Jaime Bohl, chief of colon and rectal surgery at the VCU School of Medicine, working to help patients suffering from fecal incontinence. The CELLF-BIO BioSphincter phase 1 clinical trial being led with VCU in Richmond, VA, is actively enrolling patients. https://lnkd.in/ekzezeSB
VCU Health leads clinical trial for new treatment to help people with bowel control problems | VCU Health
vcuhealth.org